| HOME >> BIOLOGY >> TECHNOLOGY |
- UGNE's oral sCT program is progressing favorably - Apart from Novartis, Unigene is developing its own version of oral sCT utilizing tablets in an improved solid dosage form (patent applied for by the Company). The Company just announced the initiation of a Phase I/II trial, with dosing to be completed by the end of February 2008. Given the favorable market opportunities surrounding an oral sCT product, we anticipate the announcement of a partnership during the first half of 2008.
- Strong positive momentum - For the quarter ended September 30, 2007, revenues rose by 34% sequentially, reflecting a 71% increase in sales and royalties relating to Fortical(R). UGNE exhibited positive operating income for the third quarter and positive cash flow from operations for the nine months ended September 30, 2007. The cash balance grew significantly during the nine-month period, increasing by over $3.6 million to over $7 million.
- Valuation - With Fortical's imminent dominance in its market, an advancing pipeline targeting large markets, a dramatically improved financial position, and huge upside potential, we believe Unigene represents a compelling risk/reward opportunity.
Investment Summary
The commercialization of peptide-based therapeutics has been hindered
by various technical challenges, and peptides have historically taken a
backseat to small molecules as active pharmaceutical ingredients (APIs) for
drug therapies. The advent of recombinant technology and recombinant
protein production in therapeutics has facilitated the development of novel
delivery systems and opened the door to new commercial opportunities for
peptide-based therapies. According to Frost and Sullivan, peptides are
poised to become "the products of the future", and the market for
peptide-based active pharmaceutical ingredients is expected to grow
'/>"/>
| SOURCE Unigene Laboratories Inc. Copyright©2008 PR Newswire. All rights reserved |